A5008861348- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Adrenal and Paraganglionic Tumors
- Advanced Breast Cancer Therapies
- Adenosine and Purinergic Signaling
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Testicular diseases and treatments
- Economic and Financial Impacts of Cancer
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
The University of Texas MD Anderson Cancer Center
2016-2025
University of Minnesota
2002-2018
University of North Carolina at Chapel Hill
2016-2018
Mayo Clinic in Florida
2018
University of Chicago
2018
University of California, Davis
2018
University of California, San Francisco
2018
Yale University
2018
WinnMed
2018
University of Minnesota System
2018
In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses patients with advanced renal-cell carcinoma. This 3 trial involving previously untreated carcinoma compared the standard-of-care sunitinib.
•Avelumab plus axitinib significantly prolonged progression-free survival versus sunitinib in advanced renal cell carcinoma.•Although overall data were immature, results favored the combination over across prespecified subgroups.•Adjusting for subsequent use of PD-1/PD-L1 inhibitors arm predicted a benefit combination.•Among all randomized patients, avelumab had longer mean duration response than sunitinib.•Avelumab on next-line therapy sunitinib. BackgroundThe phase 3 JAVELIN Renal 101...
Abstract Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for should not impede antitumor immunity. Understanding the mechanisms critical to overcome this challenge, but pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and/or synovial fluid samples from 20 patients arthritis-irAE, and unmask a prominent...
4508 Background: The JAVELIN Renal 101 (NCT02684006) phase 3 trial compared first-line treatment with avelumab + axitinib vs sunitinib in aRCC. previously met one of its primary objectives by showing significantly longer progression-free survival (PFS) pts PD-L1+ tumors; PFS, higher objective response rate (ORR), and an acceptable safety profile were also observed the overall population. OS data immature. Here we report final analysis. Methods: Pts untreated aRCC (any IMDC risk score)...
Spine stereotactic body radiotherapy (SBRT) is increasingly being applied to the postoperative spine metastases patient. Our aim was identify clinical and dosimetric predictors of local control (LC) survival. Eighty patients treated between October 2008 February 2012 with SBRT were identified from our prospective database retrospectively reviewed. The median follow-up 8.3 months. Thirty-five (44%) 18–26 Gy in 1 or 2 fractions, 45 (56%) 18–40 3–5 fractions. Twenty-one failures (26%) observed,...
<h3>Background</h3> Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated efficacy and safety pembrolizumab patients with metastatic <h3>Methods</h3> This pre-specified cohort single-center, investigator-initiated, phase II clinical trial using monotherapy malignancies. Patients must have had prior fail past 6 months before study enrollment. were enrolled from August 2016 to October...
101 Background: The phase 3 JAVELIN Renal trial in previously untreated patients (pts) with aRCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate A+Ax vs S (Motzer, ESMO 2018; LBA6_PR). Here, we report outcomes from biomarker analyses of baseline tumor samples. Methods: We correlated efficacy the results molecular tissue samples all 886 pts enrolled 101. Nephrectomy or were characterized by immunohistochemistry (CD8 PD-L1), whole-exome sequencing...
Background In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder upper tract carcinoma variant histology (BUTCVH), adrenal tumors, platinum‐refractory germ cell penile carcinoma, prostate cancer (NCT03333616). Methods Patients malignancies no prior immune checkpoint inhibitor exposure were enrolled. received at 3 mg/kg 1 intravenously every weeks for 4 doses,...
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network Investigate Therapeutic Experiences (UNITE) study, authors looked at experience with EV in patient subsets of interest which activity had not been well defined clinical trials.UNITE was retrospective study patients aUC treated recently agents. This initial analysis focused on EV. Patient data were abstracted from chart reviews...
The accumulation of immune-suppressive myeloid cells is a critical determinant resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses anti–PD-1 by modulating cells. We conducted phase 1-2 trial choose an optimal dose combined with fixed nivolumab 42 immunotherapy-naïve patients ccRCC refractory prior antiangiogenic therapies. combination demonstrated no...
Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAPdef) in tumors with 9p21 loss and hypothetically renders susceptible to synthetic lethality by antifolates targeting de novo purine synthesis. Here we report our single arm phase II trial (NCT02693717) that assesses pemetrexed MTAPdef urothelial carcinoma (UC) primary endpoint of overall response rate (ORR). Three 7 enrolled patients show (ORR 43%). Furthermore, a historic cohort...
Abstract Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination nivolumab patients locally advanced clear cell renal carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521). The primary endpoint was objective response rate (ORR) surgery null hypothesis ORR = 5% and the alternative set at...
There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings UC, the Society Immunotherapy of Cancer (SITC) International Bladder Group (IBCG) convened multidisciplinary, international consensus panel.Through open communication scientific debate small- whole-group settings, surveying, responses to questionnaires, panel developed optimal definitions state, end points,...
652 Background: Enfortumab vedotin (EV) is approved for patients (pts) with advanced urothelial carcinoma (aUC) but outcomes in pts histology variants (HV) have not been well described. We hypothesized that presence of HV would impact EV treatment outcomes. Methods: UNITE a multi-site retrospective study aUC treated targeted agents, including 650 regimens. compared to monotherapy pure UC (pUC) relative any and specific HVs. In scans after > 1 cycle EV, observed response rate (ORR) was...
537 Background: MAv is approved in pts with aUC without progression (PD) on 1L platinum-based therapy (PBT). As the pivotal EV trials had not received after PBT, data outcomes post-MAv are limited. We examined multicenter retrospective UNITE study. hypothesized that would be similar to published data. Methods: Pts who sequential MAv, then monotherapy were included. Investigator-assessed observed response rate (ORR) was assessed for evaluable scans ≥ 1 cycle using χ 2 test and logistic...
558 Background: Nivo/ipi is a standard of care first-line (1L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) but its role in variant histology RCC (vhRCC) has not been fully defined. Methods: We report single-institution experience nivo/ipi to treat 55 vhRCC between Nov. 2017 and Feb. 2024 at MD Anderson Cancer Center. Tumor response was measured by blinded radiologists using RECIST v1.1. Descriptive statistics the Kaplan-Meier method were used. Results:...